Egfr20 mutation targeted drugs include TAK-788, Pocitinib and JNJ-372. 1.TAK-788, a drug with core modification on the basis of ositinib, increases the insertion mutation activity of Egfr20, which can prolong the median progression period of non-small cell lung cancer patients by 7.3 months. 2.Pocitinib, mainly used in the treatment of advanced non-small cell lung cancer, acts more accurately on the tumor tissues and enhances the median progression-free survival time of patients. 3. JNJ-372, takes EGFR and cMet as the target, reduces their active degree and controls the growth rate of tumor tissues, the overall effect is more prominent in clinic, and the total effective rate can reach about 30%. Egfr20 mutation-targeted drugs should be selected based on the patient’s physical condition, pathology type, etc., and follow the guidance and advice of professional doctors.